All News

Daniel Drucker, MD, discusses gastrointestinal effects, hydration, pregnancy planning, and unanswered long-term safety questions.

The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.

An endocrinologist discusses the importance of history, comorbidities, lifestyle care, and outcomes beyond weight loss when choosing obesity treatment.

New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.

FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.

A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.

Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.

Daniel Drucker, MD, who coauthored the recent Endocrine Society scientific statement on obesity medicines, discusses key takeaways for primary care physicians.

Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.

Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.

Mina Fam, MD, addresses common prostate cancer misconceptions involving symptoms, elevated PSA, biopsy, and active surveillance.

New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.

Mina Fam, MD, reviews risk-based PSA interpretation, prostate MRI, biomarkers, and targeted biopsy in the modern diagnostic pathway.

The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.

Rodica Di Lorenzo, MD, explains why new headaches, migraine with aura, estrogen exposure, smoking, and pregnancy matter in stroke assessment.

Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.

The FDA accepted Organon’s MIUDELLA supplemental application, but the proposed change, supporting data, and review timeline remain undisclosed.

A urologist discusses how primary care clinicians can identify patients most likely to benefit from prostate cancer screening while limiting overdiagnosis.